Comunicati.net - Comunicati pubblicati - Coherent Market Insights Comunicati.net - Comunicati pubblicati - Coherent Market Insights Tue, 25 Jun 2019 07:46:25 +0200 Zend_Feed_Writer 1.12.20 (http://framework.zend.com) http://comunicati.net/utenti/24662/1 Asthma Therapeutics Market to Perceive Substantial Growth During 2018–2026 Mon, 24 Jun 2019 12:24:47 +0200 http://comunicati.net/comunicati/aziende/varie/572395.html http://comunicati.net/comunicati/aziende/varie/572395.html Coherent Market Insights Coherent Market Insights The Global Asthma Therapeutics Market was valued at US$ 17,582.2 million in 2018, and is expected to witness a CAGR of 1.9% during the forecast period (2018 – 2026). Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.

 

Market Dynamics

Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.

Rise in number of respiratory disease cases is expected to drive growth of the global asthma therapeutics market.

Increasing prevalence of respiratory diseases is expected to drive global asthma therapeutics market growth. For instance, according to the World Health Organization’s (WHO) report 2016, around 235 million people suffer from asthma worldwide, annually. Asthma is a progressive and chronic life-threatening respiratory disease. Hence, increasing number of respiratory disease cases support the global asthma therapeutics market growth.

Moreover, increasing awareness activities are contributing to the global asthma therapeutics market growth. For instance, in May 2019, Koninklijke Philips N.V., launched campaign to increase awareness of asthma and related respiratory diseases, especially in children. This campaign was titled as ‘Help Your Child Fight against Asthma’.

Global Asthma Therapeutics Market - Competitive Landscape

Key players operating in the asthma therapeutics market include GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2698

Global Asthma Therapeutics Market- Regional Analysis

North America asthma therapeutics market is expected to account for the largest market share during the forecast period, owing to increasing number of product approvals by regulatory authorities in this region. For instance, in September 2018, U.S. Food and Drug Administration (FDA) announced approval of new Xolair (containing-Omalizumab) prefilled syringe formulation, for treatment of allergic asthma. Xolair is manufactured by Novartis AG.

Moreover, increasing regulatory approvals of new drug for treatment of asthma is expected to boost forecast value of asthma therapeutics market in this region. For instance, in October 2018, U.S. Food and Drug Administration (USFDA) announced approval of new drug Dupixent (contains- Dupilumab), developed by the Regeneron Pharmaceuticals, for the treatment and prevention of pulmonary/respiratory diseases including moderate-to-severe asthma.

Furthermore, Asia Pacific is expected to hold significant market share in the asthma global therapeutics market over the forecast period, owing to increasing product launches by key players in this region. For instance, in April 2019, Cipla announced launch of its new inhaler Niveoli in India. It is India’s first extra-fine particle Beclomethasone-formoterol combination Hydrofluoroalkane (HFA) inhaler for adults. It is indicated for the treatment of obstructive airways diseases (OAD) such as asthma and Chronic Obstructive Pulmonary Disease (COPD).hence increasing number of product launches will support the growth of asthma therapeutics market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Evolving Industry Trends and key Insights by 2026 Mon, 24 Jun 2019 11:18:42 +0200 http://comunicati.net/comunicati/aziende/varie/572350.html http://comunicati.net/comunicati/aziende/varie/572350.html Coherent Market Insights Coherent Market Insights Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA). Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin). Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing adoption of organic and inorganic strategies by key market players. Click To Read More On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver

Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc., received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new route of administration are experimented by market players to treat MRSA infection. For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is expected to aid in growth of the MRSA drugs market over the forecast period.

Moreover, funding programs by healthcare organization will also propel drug discovery and development program, in turn leading to growth of the MRSA drug market. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individual with cystic fibrosis.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor

Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma, Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market are focusing inorganic growth strategies in order to enhance its market share and remain competitive in the market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1538

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Regional Analysis

Geographically, global methicillin-resistant staphylococcus aureus (MRSA) drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in methicillin-resistant staphylococcus aureus (MRSA) drugs market, owing to increasing research and development studies by key market players to come up with new drug. For instance, in 2016, Allergan plc received US FDA approval for Dalance in injectable form for acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). Asia Pacific is expected to witness fastest growth over the forecast period. This is due to larger patient pool and increasing market player’s strategies to expand their geographical reach in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Structural Heart Devices Market Estimated to Record Highest CAGR by 2026 Mon, 24 Jun 2019 09:10:04 +0200 http://comunicati.net/comunicati/aziende/varie/572238.html http://comunicati.net/comunicati/aziende/varie/572238.html Coherent Market Insights Coherent Market Insights Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to some disease. Structural heart diseases is a non-coronary abnormality of heart, which does not affect the blood vessels in the heart. Common structural heart condition includes atrial septal defect, patent foramen oval, ventricular septal defect, paravalvular leak, arterial/venous fistulae, and congenital heart disease. Click To Read More On Structural Heart Devices Market.

Structural Heart Devices Market Drivers

In 2017, Medtronic plc. received the U.S. Food and Drug Administration (FDA) approval for its new CoreValve Evolut PRO valve for the treatment of severe aortic stenosis in symptomatic patients who are at high or extreme risk for open heart surgery. Moreover, the company has launched CoreValve Evolut PRO valve in the U.S. market in the same year. In 2017, Medtronic plc. received CE Mark for its CoreValve Evolut R 34 mm valve and launched it in European market. CoreValve Evolut R 34 mm is the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. In 2015, Edwards Lifesciences Corporation, an U.S.-based company focused on heart valves and hemodynamic monitoring received U.S. Food and Drug Administration (FDA) approval for its Edwards SAPIEN 3 valve, a transcatheter aortic heart valve used for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. Furthermore, companies operating in the area are looking to expand product portfolio through inorganic growth. For instance, in 2015, CryoLife, Inc., an U.S.-based medical device company acquired the U.S. based On-X Life Technologies Holdings, Inc., a privately held mechanical heart valve company. CryoLife, Inc. entered in mechanical valve market with On-X Life Technologies Holdings, Inc.’s products with this strategic acquisition.

Structural Heart Devices Market Key Players

Key players in global structural heart devices market include Abbott Laboratories, Medtronic Plc., Edwards Lifesciences Corporation, Boston Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook Group Incorporated, Endologix Inc., and W. L. Gore & Associates, Inc. Key players in the market are focused on strategic merger and acquisition in order to expand its structural heart device product portfolio.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1559

For instance, in 2017, Edwards Lifesciences Corporation, a US based medical device manufacturer, acquired Harpoon Medical, Inc. in US $ 100 cash and additional US $ 150 million in milestone payments over 10 years. With this strategic acquisition Edwards Lifesciences Corporation has widen its offerings with mitral valve repair technology, which is designed to reduce the amount of time required for mitral valve surgery.

Structural Heart Devices Market Regional Analysis

North America is expected to hold a dominant position in global structural heart devices market, to take on research for the development of novel product and subsequent launches by major key players present in the region. For Instance, in 2017, Edwards Lifesciences Corporation, a US-based company is focusing on Launch of SAPIEN 3 Ultra and CENTERA Valves. SAPIEN 3 Ultra system is a next-generation platform with expandable Axela technology and on-balloon delivery design. The novel product is expected to accelerate the make procedure with less chances of mistakes.

Furthermore, Europe is expected to witness significant growth in structural heart devices market, owing to increasing prevalence of Valvular Heart Disease (VHD) in the region. In 2017, incidence of VHD was 63.9 per 100 000 person-years, with aortic stenosis (AS; 47.2%), mitral regurgitation (MR; 24.2%) and aortic regurgitation (AR ; 18.0%). The study analyzed nationwide hospital data between 2003 and 2010 to reach this conclusion.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and the potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
# 3200
Seattle, WA 98154
Tel: + 1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Contract Research Organization Services Market Size & Share to See Modest Growth Through 2026 Sat, 22 Jun 2019 11:50:26 +0200 http://comunicati.net/comunicati/aziende/varie/572018.html http://comunicati.net/comunicati/aziende/varie/572018.html Coherent Market Insights Coherent Market Insights The contract research organization services are the organizations that provide support to the biopharmaceutical or biotechnological industries and academic institutes in the form of outsourced pharmaceutical research services. The CROs work for both drugs and medical devices and also range from large, international full service organizations to small niche specialty groups to fulfill the clients’ requirement. Initially, the pharmaceutical companies used to carry their own discovery work, along with every other elements to get the drug or medical device in the market. But nowadays, any research work required by biotechnology or pharmaceutical companies from designing assay to planning and running the clinical trials are outsourced from CROs. Outsourcing or partnering with a CROs by the biotechnological companies provide a strategic benefit to the manufacturers, such as cost and time saving in the development and approval process of new drug or therapeutic device, which is expected to increase the demand for CROs. Click To Read More On Contract Research Organization Services Market.

Furthermore, increasing demand for effective biotherapies and increasing competition between manufacturers to discover new drugs are expected to foster growth of CROs market. Increasing need for product development is leading to high demand for experience and high skilled professionals to implement and conduct the biotechnological research and clinical trials, which can be provided by CROs.

Contract Research Organization Services Market Dynamics

Increasing number of Food and Drug administration (FDA) approvals are supporting the growth of biopharma industry, which in turn is fuelling growth of the CROs market. According to article published in Nature, the U.S. FDA approved 46 novel drugs for various indication by the agency’s Center for Drug Evaluation and Research (CDER) in 2017 and 22 drugs in 2016. As the drug companies and few research institutes face challenges in marketing their product due to limited resources and huge capital investment, which decreases the affordability of errors in research work. Therefore CROs play an important role in reducing the cost of research and help in successful clinical development program, which is the most important step of drug development process. As developing a safe and efficacious biological product for human is demonstrated through clinical trials.

Contract Research Organization Services Market - Competitive Analysis

Key players operating in the global contract research organization services market include IQVIA, LabCorp, PAREXEL, ICON plc, PPD, PRA Health Sciences, Syneos Health, Charles River, Wuxi PharmaTech, Medpace Holdings, SGS, Envigo, and MPI Research.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1592

Contract Research Organization Services Market - Regional Insights

North America market accounted for the largest share in the contract research organization services market, followed by Europe in 2016. This is attributed to increasing number of biotechnology-based companies with rising demand for CROs outsourcing services. Furthermore, increasing number of clinical trials and robust pipeline of Novartis, AstraZeneca, Merck and Pfizer, Inc. in the North America region are the factors responsible for growth of market in North America region over the forecast period.

Contract Research Organization Services Market - Taxonomy:

By Type:

  • Clinical Research Services

  • Early Phase Development Services

  • Laboratory Services

  • Consulting Services

By Therapeutic Application:

  • Oncology

  • Infectious Diseases

  • Central Nervous System (CNS) Disorders

  • Immunological Disorders

  • Cardiovascular Diseases

  • Respiratory Disorders

  • Diabetes

  • Other Therapeutic Areas

In Asia Pacific region, the countries such as China and India particularly have increasing number of clinical trials for many application areas. Furthermore, due to large patient population, these countries provides a huge opportunity to the manufactures to market their drugs in Asia Pacific region, which is considered as major driver for rapid growth of CRO services. Besides, in some cases, the multinational companies are not allowed to conduct first-in-human Phase I studies in India and China where CROs plays a vital role to conduct such projects under such circumstances.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Stethoscope Market Demands and Growth Prediction 2018 to 2026 Fri, 21 Jun 2019 13:01:26 +0200 http://comunicati.net/comunicati/aziende/varie/571892.html http://comunicati.net/comunicati/aziende/varie/571892.html Coherent Market Insights Coherent Market Insights Stethoscope is an acoustic medical device used for auscultation based physical examination of an animal or humans. The resonator placed beneath the small disc at one end amplifies sound of lungs, heart, esophagus or fetal heart rate. Stethoscope is a fundamental component of physical examination for a healthcare profession. Major drivers for growth of the stethoscope market are increasing incidence of cardiovascular disease, rising number of healthcare professionals, and improving healthcare facilities. Moreover, market players are introducing more user friendly technologically advanced products with Bluetooth connectivity or wireless digital stethoscope, which is expected to boost growth of the Stethoscope Market.

Stethoscope Market Drivers

Increasing product launches by key players with advanced technologies is expected to aid in growth of the global stethoscope market during the forecast period. For instance, in March 2018, a research team developed an open-source, clinically validated template for a 3D printed stethoscope for application in the areas that have limited access to medical supplies. Moreover, in April 2018, Steth IO launched digital stethoscope named Steth IO. The product is built directly into the protective case of the physician’s iphone. It runs on an app that allows visualization of heart or lung sounds directly on the phone’s screen, when held against patient’s chest. Furthermore, it enables physician to store the records in the app, which can be shared in case of a second opinion. Steth IO received FDA approval in 2016. In 2015, Eko received US FDA clearance to launch Eko Core, a next generation digital stethoscope.

High incidence of heart diseases is expected to be another factor for growth of the market. Stethoscope is an important component that aids clinicians in diagnosis of cardiovascular disease, which affects 1 in 4 people in US, according to Center for Disease Control and Prevention (CDC). According to American Heart Association, 2018, cardiovascular disease is the leading cause of death, globally. Furthermore, according to same source, it is estimated that everyday 2,300 people in the U.S. die of cardiovascular disease, which means on an average 1 death per 38 seconds.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1613

Stethoscope Market Taxonomy

By Product Type

  • Dual Head Stethoscope

  • Single Head Stethoscope

  • Triple Head Stethoscope

By Application

  • Humans

  • Veterinary

By End Users

  • Hospitals

  • Clinics

  • Academic & Institutes

  • Homecare settings

  • Others

Stethoscope Market– Competitive Lanscape

Key players operating in the stethoscope market are 3M Company, Cardionics, Inc., Heine Optotechnik GmbH & Co. KG, American Diagnostics Corp, Medline Industries, Inc., Welch Allyn, Inc., GF Health Products, Inc., and Rudolf Riester GmbH.

Moreover, increasing geriatric population, who are more prone to diseases rising the demand for frequent diagnosis under several medical conditions expected to propel the growth of stethoscope market. For instance, the global geriatric population is estimated to be 962 million, which comprises 13% of the total global population, in 2017 as per United Nation Organization. According to their forecast, this geriatric population worldwide is expected to be reach 1.4 billion in 2030 and 2.1 billion by 2050.

Stethoscope Market- Regional Analysis

Based on geography, the stethoscope market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in stethoscope market, owing to the increasing number of new product launches by the key players in U.S. North America market is followed by Europe attributed to the increasing number of hospitals and clinics and medical professionals. For instance, according to Eurostat, around 1.8 million physicians are working in the European Union, while the comparison between 2005 and 2015 showed that the number of medical doctors graduating per 100,000 inhabitants rose to 12.4 medical doctors in 2015 as compared to 2005 (9.5 medical doctors per 100,00 inhabitants).

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Drug Discovery Market Best Productivity Supply Chain Relationship, Development by 2026 Fri, 21 Jun 2019 11:43:51 +0200 http://comunicati.net/comunicati/aziende/varie/571858.html http://comunicati.net/comunicati/aziende/varie/571858.html Coherent Market Insights Coherent Market Insights Advancements in the field of biotechnology and pharmaceuticals, in order to identify active ingredients in the form of drugs through drug discovery process, is gradually gaining pace in the market. This drug discovery process involves screening of chemical libraries, identification of the active ingredients for a natural remedy or by serendipitous discovery. Emergence of new diseases, which include viral or infectious diseases leads to high demand for drug discovery for these conditions. However, development of drugs is complex, costly, and risky process. Click to Read More on Drug Discovery Market.

The objective of drug discovery is to recognize the investigational drug success rates by stages, pre-clinical studies, investigational new drug application-Phase I, Phase II, Phase III studies, new drug application, and phase IV studies. The success during drug discovery process is very low, as according to data published by Journal Research & Review 2016.

Drug Discovery Market Dynamics

A patent cliff provides an opportunity for manufactures to collaborate and participate in current drug discovery model to sustain in the market. Manufacturers such as, Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead lost their patent in 2017, with some of their respective big sellers that cover a range of indications such as multiple sclerosis, HIV, erectile dysfunction, and cancer. Such patent loss forces companies to introduce innovative products to retain their revenues and increase their revenue. After patent expiration, generic manufacturers enter the market and provide drugs that are equivalent to the innovator’s drugs, however, at a significantly lower price. Therefore, manufacturers are focusing on developing new and innovative products to sustain in the competitive market.

Increasing prevalence of wide range of disease such as cancer, cardiovascular, and CNS-related disorders with patent expiration of blockbuster drugs are some of the driving factors for growth of the drug discovery market. According to the World Cancer Research Fund International, 2015, an estimated 124,000 new cases of myeloma were diagnosed globally in 2015, which accounted for 0.8% of the total cancer cases. The mortality rate of the disease is around 0.9% of all cancer deaths, accounting for 87,000 deaths each year. Therefore, key manufacturers are actively involved in the development of immunotherapies targeting B-cell maturation antigen (BCMA) such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, and antibody drug conjugates (ADCs). For instance, in 2012, the University of Pennsylvania and Novartis entered into an exclusive global research and licensing agreement to study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

Drug Discovery Market - Competitive Analysis

Major players operating in the market are Pfizer Inc., GlaxoSmithKline LLC, Merck & Co. Inc., Agilent Technologies Inc., Eli Lilly and Company, F Hoffmann-La Roche Ltd, Bayer AG, Abbott Laboratories Inc., AstraZeneca PLC, and Shimadzu Corp., among others.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1631

Drug Discovery Market - Regional Insights

North America accounted for the largest share in the drug discovery market, followed by Europe market in 2016. This is attributed to presence of a large number of top pharmaceutical and biotech companies, Pfizer, Inc., Merck, GlaxoSmithKline, Novartis and many more in this region. Furthermore, favorable regulatory framework and regulatory policies for investors for research and development of new drugs augments growth of drug discovery market in the region. The US Regulatory Framework provides for 3 distinct regulatory approval pathways outlined in the Food, Drug, and Cosmetics Act (FD&C Act), which allows the registration of novel compounds, new drugs containing similar ingredients to previously approved products and generic copies of previously approved products in systematic way helping the pharmaceutical companies to gain approval over the new drugs.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of drug discovery in Asia Pacific region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Mitochondrial Disorders Treatment Market Upcoming Trends, Demand and Analysis Till 2026 Fri, 21 Jun 2019 09:38:58 +0200 http://comunicati.net/comunicati/aziende/varie/571742.html http://comunicati.net/comunicati/aziende/varie/571742.html Coherent Market Insights Coherent Market Insights Mitochondrial disorders are inherited chronic disorders characterized by a wide range of biochemical and genetic mitochondrial defects and mutations. The disorder affects multiple organs, which includes brain, heart, liver, skeletal muscles, kidney, and respiratory systems. The patients with mitochondrial disorders often suffer from muscle weakness, exercise intolerance, and fatigue due to reduction in mitochondrial respiration, which is caused due to mitochondrial DNA mutations leading to reduced ability to produce cellular adenosine triphosphate (ATP). Click To Read More On Mitochondrial Disorders Treatment Market.

Despite major advances in understanding of the molecular mechanisms, currently there are no effective treatments for the disease. The treatment of mitochondrial disorders is mostly performed with different vitamins, co-factors, off-label drugs approved for other indications, and nutritional supplements. However, the research organizations and pharmaceutical companies are involved in development of novel drugs with technology advancements including the use of biomarkers, replacement therapies and sophisticated trial designs, thus creating a lucrative opportunity for the market growth.

Mitochondrial Disorders Treatment Market: Market Dynamics

Increasing prevalence of mitochondrial disorders causing significant morbidity and mortality combined with the higher potential of genetic transmission to the next generation are the factors driving the market growth. According to the Wellcome Center for Mitochondrial Research, 2015, about 10 people per 100,000 have a mitochondrial disorders, which often express first in early childhood. According to the Genetic and Rare Disease Information Center, women with mitochondrial genetic disorders have 50% chance with each pregnancy of passing along the altered gene to the offspring, thus indicating the rising burden of the disease. Also, the mitochondrial disorders treatment market is expected to gain significant traction in the future, as the pharmaceutical drugs approved for the treatment of primary mitochondrial disease have orphan drug status, thereby having a greater potential for market approval than conventional pharmaceuticals. Moreover, the approval of novel drug molecules from the regulatory agencies is expected to create a lucrative opportunity for the growth of mitochondrial disorders treatment market.

Hearing Diseases and Mitochondrial Disorders is expected to augment market growth. For instance, in April, 2018, GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2-ND4) in treating a mitochondrial disease- Leber Hereditary Optic Neuropathy (LHON).

Mitochondrial Disorders Treatment Market: Competitive Landscape

Key players operating in the global mitochondrial disorders treatment market include Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., and Stealth Biotherapeutics.

Ask For Sample Copy Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1650

Mitochondrial Disorders Treatment Market: Regional Dynamics

Regional segmentation of the global mitochondrial disorders treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North American is expected to hold a dominant position in the global mitochondrial disorders. According to the Institute of Medicine, US, 2015, an estimated 30,000 Americans are suffering from inherited defects in their mitochondria. Also, the North American Mitochondrial Disease Consortium (NAMDC), an estimated 1,000 children per year are born with some form of mitochondrial disease in the US

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunities.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
# 3200
Seattle, WA 98154
Tel: + 1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Perfusion System Market: Business Planning Research, Reviews & Comparison of Alternatives Till 2026 Thu, 20 Jun 2019 12:19:47 +0200 http://comunicati.net/comunicati/aziende/varie/571423.html http://comunicati.net/comunicati/aziende/varie/571423.html Coherent Market Insights Coherent Market Insights Perfusion can be defined as a process of delivering oxygenated blood to the tissues of the body. Perfusion systems are majorly employed in organ transplant surgeries, as they help replace the function of the organ during the operation by pumping blood throughout the body. Over the recent past, the global perfusion system market has witnessed lucrative growth due to the increasing product launches by key players in market and the increasing number of organ transplants. For instance, according to data published by Organ Procurement and Transplantation Network (OPTN), in the U.S., over 117,000 men, women, and children were on the national transplant waiting list, as of July 2017 and 17,155 organ transplants were performed till July 2017. Click To Read More On Perfusion System Market.

Perfusion System Market Drivers

Increasing number of approvals and launches of new perfusion systems is expected to be major factor influencing growth of the perfusion system market in near future. For instance, in 2014, U.S. Food and Drugs Administration approved Xvivo Perfusion AB’s Xvivo Perfusion System (XPS) with STEEN solution, used in preserving initially unacceptable donor lungs while they are being evaluated as potentially viable transplantable organs. In February 2018, Paragonix Technologies, Inc. received approval for its new Paragonix SherpaPak Cardiac Transport System and SherpaPerfusion Cardiac Transport System in Europe. The SherpaPak Cardiac Transport System is used for the hypothermic static preservation and transport of donor hearts, and the SherpaPerfusion Cardiac Transport System consists of a single-use, disposable device for hypothermic oxygenated perfusion preservation and transport of donor hearts. The increasing investment by major key players in the market is also expected to fuel growth of the global perfusion system market in the near future.

For instance, in January 2018, Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) raised around US$ 26.3 Mn as part of a Series D financing round. The raised amount will be used in the development and commercialization of PiCSO Impulse System. Furthermore, the increasing demand for organ transplants is also expected to increase demand for perfusion system and increase its market growth in near future. For instance, according to the data published by National Kidney Foundation as of 2016, around 100,791 people in the U.S. are waiting for kidney transplants.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1661

Perfusion System Market Key Players

Key players operating in the perfusion system market include XVIVO Perfusion AB, Paragonix Technologies, Inc., Organ Assist B.V., Organ Recovery Systems, Organ Transport Systems, Waters Medical Systems, TransMedics, Inc., OrganOx Limited, and Bridge to Life Ltd. Key players in the market are focusing on launching new perfusion systems in order to increase their sales. For instance, March 2018, Sartorius Stedim Biotech SA launched its new ambr 250 high throughput (ht) perfusion, a new automated parallel bioreactor system. The ambr 250ht perfusion system is designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies.

Perfusion System Market Regional Analysis

North America is expected to hold a dominant position in the global perfusion system market due to high presence of key players and increasing collaborations among them to expand their product’s reach in the region. For instance, in 2016 Medtronic plc., a U.S. - based medical device company, entered into a strategic partnership with Spectrum Medical Ltd. for the distribution of Spectrum Medical’s new Quantum Perfusion Systems in Canada and other regions. In 2017, Paragonixc Technologies, Inc. entered into a strategic distribution agreement with MBA Medical to market Paragonix Technologies’ SherpaPak Cardiac and Kidney Transport Systems, in the Southern part of U.S. Furthermore, Europe is expected to witness significant growth in the global perfusion system market, owing to increasing approvals of new perfusion systems in the region. In 2016, Limflow SA received CE marking for its latest percutaneous LimFlow System designed for venous arterialization of the lower limbs for patients with end-stage risk of limb amputation for Critical Limb Ischemia.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Electric Wheelchair Market Health Improvement Aspects, Expert Reviews, Research 2018 to 2026 Thu, 20 Jun 2019 10:04:14 +0200 http://comunicati.net/comunicati/aziende/varie/571289.html http://comunicati.net/comunicati/aziende/varie/571289.html Coherent Market Insights Coherent Market Insights The Global Electric Wheelchair Market was valued at US $ 2.911.5 Mn in 2018, and is expected to witness CAGR of 17.1% during the forecast period (2018 - 2026).

 

Technological advancements in electric wheelchairs to improve medical conditions such as physical disability due to providing easy mobility, is expected to boost growth of the electric wheelchair market. Manual wheelchairs are designed to overcome mobility issues in physically disabled people. However, a manual wheelchair has been found to be a difficult task as it may cause fatigue. Thus, people are shifting towards electric wheelchairs as they offer easy mobility and associated functions with multiple functions, wireless programming and remote monitoring. Rising number of people with disabilities, meningitis, and workplace injuries.

Market Dynamics

Increasing product launches of high-technology electric wheelchair For instance, in December 2017, Quantum Rehab's front wheel drive electric wheelchair, 4Front Power Base, was launched in the UK and Ireland. The 4Front is equipped with independent, automotive-grade Smooth Ride Suspension (SRS) that provides comfort and ride quality. Moreover, in May 2017, Numotion, a provider of Complex Rehab Technology (CRT), developed Tek RMD (Robotic Mobilization Device), a motorized standing wheelchair and made available in the US

Collaborations by the key players in order to enhance their wheelchair product portfolio is contributing to growth of the electric wheelchair market. For instance, in September 2014, Ottobock collaborated with MND Association and launched the new B400 Neuro Power Wheelchair, a new power wheelchair designed for people with motor neuron disease (MND). The B400 Neuro Power Wheelchair was developed as part of a MND Association initiative funded by the Department of Health, England.

Increasing number of product launches is expected to drive growth of the Electric Wheelchair Market

Increasing initiatives by key players in the development of the pediatric electric wheelchair market. For instance, in January 2015, Sunrise Medical (US) LLC introduced new Zippie ZM-310 pediatric power wheelchair featuring the smallest mid-wheel-drive base. The product was revised and updated as for the ANSI / RESNA standards. Moreover, in 2014, Invacare Corporation launched a new Invacare Fox electric wheelchair. It is designed to enable adult users to maximize independence in everyday life. Fox electric wheelchair provides considerable maneuverability indoors, and traction outdoors.

Electric Wheelchair Market - Competitive Landscape

Key players operating in the electric wheelchair market include Invacare Corporation Sunrise Medical, Permobil, Pride Mobility Products Corporation, Drive Devilbiss Healthcare, Hoveround Corporation, Ottobock Healthcare, 21st Century Scientific, Inc., Meyra GmbH, LEVO AG, and Merits Co. Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1758

Electric Wheelchair Market- Regional Analysis

Regional segmentation of the global electric wheelchair market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is anticipated to witness significant electric wheelchair market share, owing to initiatives by market players to establish their product portfolio in North American countries. For instance, in August 2018, Sunrise Medical LLC acquired Magic Mobility, a manufacturer of powered wheelchairs. With this acquisition, Sunrise Medical LLC aims to include powered wheelchairs in their product portfolio.

Asia Pacific is expected to witness significant growth over the forecast period owing to increasing investments by manufacturers in order to expand their product portfolio. For instance, in September 2018, Whill Inc., a Tokyo-based company, raised around US$ 44.5 million from 13 companies. Moreover, the company sold its first product, Model A, in 2014 and second product Model Ci in April 2017 in the U.S.

Europe is also expected to have meteoric growth in the electric wheelchair market, owing to increasing number of physically-challenged people in the region. For instance, according to the Family Resources Survey, 2016-17, there were 13.9 million physically-challenged people in the U.K., out of which children accounted for 8% and working age adults and pension age adults accounted for 19% and 45%, respectively.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
# 3200
Seattle, WA 98154
Tel: + 1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Electric Wheelchair Market Health Improvement Aspects, Expert Reviews, Research 2018 to 2026 Thu, 20 Jun 2019 10:01:51 +0200 http://comunicati.net/comunicati/aziende/varie/571282.html http://comunicati.net/comunicati/aziende/varie/571282.html Coherent Market Insights Coherent Market Insights The Global Electric Wheelchair Market was valued at US$ 2,911.5 Mn in 2018, and is expected to witness a CAGR of 17.1% during the forecast period (2018 – 2026).

 

Technological advancements in electric wheelchairs to improve medical conditions such as physical disability caused due to lower limbs dysfunction by providing easy mobility, is expected to boost growth of the electric wheelchair market. Manual wheelchairs are designed to overcome mobility issue in physically disabled people. However, a manual wheelchair has proven to be a difficult task as it may cause fatigue. Thus, people are shifting towards electric wheelchairs as they offer easy mobility and are associated with multiple functions, including wireless programming and remote monitoring. Rising number of disability cases caused by factors such as increasing number of spinal cord injuries, meningitis, and workplace injuries among others, are expected to increase demand for electric wheelchairs.

Market Dynamics

Increasing product launches of high-technology electric wheelchairs is expected to drive growth of the electric wheelchair market. For instance, in December 2017, Quantum Rehab’s front wheel drive electric wheelchair, 4Front Power Base, was launched in the U.K. and Ireland. The 4Front is equipped with independent, automotive-grade Smooth Ride Suspension (SRS) that provides comfort and ride quality. Moreover, in May 2017, Numotion, a provider of Complex Rehab Technology (CRT), developed Tek RMD (Robotic Mobilization Device), a motorized standing wheelchair and made available in the U.S.

Collaborations by the key players in order to enhance their wheelchair product portfolio is contributing to growth of the electric wheelchair market. For instance, in September 2014, Ottobock collaborated with MND Association and launched the new B400 Neuro Power Wheelchair, a new power wheelchair designed for people with motor neurone disease (MND). The B400 Neuro Power Wheelchair was developed as part of a MND Association initiative funded by the Department of Health, England.

Increasing number of product launches is expected to drive growth of the Electric Wheelchair Market

Increasing initiatives by key players in development of pediatric powered wheelchairs are expected to show significant growth in the pediatric segment of the electric wheelchair market. For instance, in January 2015, Sunrise Medical (U.S.) LLC introduced new Zippie ZM-310 pediatric power wheelchair featuring the smallest mid-wheel-drive base. The product was revised and updated as per the ANSI/RESNA standards. Moreover, in 2014, Invacare Corporation launched a new Invacare Fox electric wheelchair. It is designed to enable adult users to maximize independence in everyday life. Fox electric wheelchair provides considerable maneuverability indoors, and traction outdoors.

Electric Wheelchair Market - Competitive Landscape

Key players operating in the electric wheelchair market include Invacare Corporation Sunrise Medical, Permobil, Pride Mobility Products Corporation, Drive Devilbiss Healthcare, Hoveround Corporation, Ottobock Healthcare, 21st Century Scientific, Inc., Meyra GmbH, LEVO AG, and Merits Co. Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1758

Electric Wheelchair Market- Regional Analysis

Regional segmentation of the global electric wheelchair market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is anticipated to witness significant electric wheelchair market share, owing to initiatives by market players to establish their product portfolio in North American countries. For instance, in August 2018, Sunrise Medical LLC acquired Magic Mobility, a manufacturer of powered wheelchairs. With this acquisition, Sunrise Medical LLC aims to include powered wheelchairs in their product portfolio.

Asia Pacific is expected to witness significant growth over the forecast period owing to increasing investments by manufacturers in order to expand their product portfolio. For instance, in September 2018, Whill Inc., a Tokyo-based company, raised around US$ 44.5 million from 13 companies. Moreover, the company sold its first product, Model A, in 2014 and second product Model Ci in April 2017 in the U.S.

Europe is also expected to have meteoric growth in the electric wheelchair market, owing to increasing number of physically-challenged people in the region. For instance, according to the Family Resources Survey, 2016-17, there were 13.9 million physically-challenged people in the U.K., out of which children accounted for 8% and working age adults and pension age adults accounted for 19% and 45%, respectively.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Orlistat Market Drivers is Responsible to for Increasing Market Share, Forecast 2026 Thu, 20 Jun 2019 07:59:32 +0200 http://comunicati.net/comunicati/aziende/varie/571146.html http://comunicati.net/comunicati/aziende/varie/571146.html Coherent Market Insights Coherent Market Insights Increasing number of awareness campaigns for weight management is expected to be a major driver for Orlistat market growth. For instance, in 2013, Roche Holding AG, a pharmaceutical company, launched its new campaign ‘New You Weight Consciousness Advocacy Campaign’, with an aim to increase awareness among the populace regarding obesity and its treatment options. Such awareness campaigns is expected increase the adoption of weight management medication treatments, which in turn, is expected to boost growth of the Orlistat Market size.

Re-launch of Orlistat products is expected to drive the market growth. For instance, in February 2018, H2 Pharma, LLC. partnered with Cheplapharma Arzneimittel GmbH and re-launched Xenical Capsules, which was acquired from F.Hoffman-La Roche. Xenical capsules were re-launched to increase awareness regarding medication related to weight management, this in turn, is expected to boost orlistat market growth.

Robust pipeline is expected to boost the market growth over the forecast period. For instance, orlistat by University of Texas South Western Medical center is in phase 2 since 2015. Orlistat is used for the treatment of hyperlipoproteinemia type 1. Hyperlipoproteinemia type 1 is caused due to deficiency of lipoprotein lipase. SLx-4090 by University of Texas South Western Medical center is in phase 2 to study its effectiveness in combination with Orlistat. SLx-4090 is used to treat high blood fat level mostly observed in hyperlipoproteinemia type 1 patients.

Rising prevalence of obesity is expected to fuel orlistat market growth. According to a survey conducted by National Family Health Survey in 2015, in India, over 9.8 million men and over 20 million women were recorded to be obese. India stands second-highest in the world for obese children, with the number constantly increasing by 3-5 million patients every year.

Orlistat Market Key Players:-

Key players operating in the Orlistat market include Roche Holding AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd, Sandoz Pharmaceuticals, STADA–VN J.V. Co., Ltd., Hexal AG., National Company for Pharmaceutical Industry, Lunan Pharmaceutical group Corporation Ltd., ZEIN Pharmaceutical Co. Ltd., HISUN Pharmaceuticals Co. Ltd., Taj Pharmaceuticals Ltd., D.M. Pharma, China Zhongshan Pharma Co. Ltd., and Kabir Life Sciences and Research Pvt. Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1878

Orlistat Market Regional Analysis:-

North America is expected to hold a dominant position in the global orlistat market, owing to high prevalence of obesity in the region. According to a study conducted by National Institute of Health in 2016, over 38% of adults aged 20 years and above are obese, over 17.2% of children aged 7 years and above are obese, and over 30% of the population is considered to be overweight in the U.S. According to a study conducted by World Health Organization, in 2015, over 40 million children aged 5 years and above were overweight in the U.S. Thus, high prevalence of obesity is expected to fuel North America Orlistat market growth over the forecast period.

Europe Orlistat market is expected to show significant growth due to expected launch of new generic version of Orlistat over the forecast period. For instance, in 2011, Teva Pharmaceutical Industries Ltd., launched generic version of Xenical Capsules in the U.K., which was manufactured by Roche Holding AG. Xenical Capsules is used for the treatment of obesity as well as for those whose BMI is greater than or equal to 30kg/m2 and overweight patients. This in turn, is expected to boost Orlistat market growth, as the drug seems more affordable thus, being accessible to a large pool of patients.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Laboratory Accessories Market Is Forecasted To Witness A Thriving Growth By 2026 Wed, 19 Jun 2019 15:59:48 +0200 http://comunicati.net/comunicati/aziende/varie/571051.html http://comunicati.net/comunicati/aziende/varie/571051.html Coherent Market Insights Coherent Market Insights Laboratory (lab) accessories refer to the tools used for conducting scientific research or experiments, and may also be used for teaching practical science. Lab accessories play a very crucial role in laboratories to provide reliable, accurate, and expeditious outcomes. Lab accessories are portable and are used in hospitals, clinics, diagnostic centers, and pathological centers among others. Laboratory accessories include laboratory instruments, general lab equipment, glassware, consumables, and other accessories. Click To Read More On Laboratory Accessories Market.

In 2014, National Science Foundation’s (NSF) annual Business Research and Development and Innovation Survey (BRDIS) data tracked the research activities of 46,000 companies. According to their survey, the drug companies have increased their investment on research & development from US$ 3 billion in 2008 to US$ 8.1 billion in 2014. NSF also stated that there is slow, however, steady rise in spending of basic research by universities and private foundations. These factors are expected to boost the global laboratory accessories market growth over the forecast period.

Global Laboratory Accessories Market Drivers:-

Continuous laboratory product launches due to increasing demand for laboratory accessories is expected to support the global laboratory accessories market growth over the forecast period. There is a constant increase in demand for laboratory accessories, due to growing competition in pharmaceutical and diagnostic industries (as lab accessories are basic requirements to run a laboratory). In order to meet the ever growing demand for lab accessories, manufacturers have to keep on introducing newer products with advanced technology to support the lab automation.

For instance, along with conventional lab accessories, products such as microplates and modular lab tables are also gaining popularity. Technological advancement aimed at improving utility and ease of handling is expected to support growth of global laboratory accessories market over the forecast period. Products offered by manufacturers such as Thermo Fisher Scientific include Dimension 4 Modular Lab Tables, Microplate Carousel, Plate Feeder Carousel, and Microplate Delidders. Dimension 4 Modular Lab Tables provide a highly scalable, flexible, and a stable platform for lab systems and work stations. Micro Plate Carousel provides access to 104 deep well microplates and 200 microplates. Microplate Delidders automates the storage, replacement of lids and storage of microplates.

Key players of Global Laboratory Accessories Market:-

Key players operating in the global laboratory accessories market include Thermo Fisher Scientific, Tecan group, Becton, Dickinson and Company, Corning Incorporated, Bio-Rad Laboratories, Hamilton Company, Analytik Jena, Greiner Bi-one, and Brooks Automation.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2035

Global Laboratory Accessories Market Regional Insights:-

North America laboratory accessories market is expected to witness significant growth over the forecast period. Presence of leading manufacturers, robust research and development activities, and continuous demand for lab accessories is expected to support global laboratory accessories market growth over the forecast period. For instance, manufacturers such as Thermo Fisher Scientific have high presence in North America, which provides innovative lab accessory solutions in the regional market.

Europe laboratory accessories market is also expected to witness significant growth over the forecast period due to rising disease prevalence and increasing research and development of drug therapies. According to World Health Organization (WHO), there is a considerable increase in the number of patients suffering from measles during the year 2016-2017 in Europe, which would in turn increase the number of disease diagnosis centers in the region. These factors are expected to support the global laboratory accessories market growth in the respective regions.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Non-Insulin Therapies for Diabetes Market Is Thriving According To New Report For 2026 Wed, 19 Jun 2019 14:08:23 +0200 http://comunicati.net/comunicati/aziende/varie/571006.html http://comunicati.net/comunicati/aziende/varie/571006.html Coherent Market Insights Coherent Market Insights Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces. Non-insulin-based medication works with different mechanism of action to reduce blood glucose level and maintain it for optimum glycemic control. For instance, some agents increase the insulin release from pancreatic cells (Sulfonylureas), some agents increase glucose uptake by periphery and reduces hepatic glucose output (Biguanides), some agents slow down digestion of starch in small intestine (alpha glucosidase inhibitors), and some medication reduces post meal sugar by blocking certain enzymes (Incretin mimetics). Click To Read More On Non-Insulin Therapies for Diabetes Market.

Non-Insulin Therapies for Diabetes Market Dynamics

Increasing global incidence and prevalence of diabetes is expected to fuel growth of the non-insulin therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide prevalence of diabetic patients was around 425 million, of which around 400 million patients were suffering from type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S.

The global economic burden of diabetes is high and is expected to substantially increase over the forecast period. According to the American Diabetes Association research in March 2018, the total costs of diagnosed diabetes have risen to US$ 327 billion in 2017 from US$ 245 billion in 2012. Therefore, non-insulin therapies for diabetes market is expected to witness growth in the near future.

Moreover, companies are launching new products and combination therapies in the market, which is expected to drive growth of the global non-insulin therapies for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semiglutide), which is once a week GLP-1 analog, would increase the patient compliance. In December 2017, FDA approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which is jointly developed by the Merck & Co. and Pfizer Inc. and in January 2018, the European Medicines Agency (EMA) granted approval for the same in Europe.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2042

Non-insulin Therapies for Diabetes Market: Competitive Landscape

Key players operating in the global non-insulin therapies for diabetes market include AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.

Non-insulin Therapies for Diabetes Market: Regional Insights

On the basis of region, the global non-insulin therapies for diabetes market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to drive growth of the non-insulin therapies for diabetes market due to highest diabetes expenditure in the U.S. According to the International Diabetes Federation (IDF), in 2017, around 17,100 new cases of diabetes were detected in the U.S. Asia Pacific is one of the most lucrative region due to increased diabetes burden in China and India, collectively having over 180 million patients suffering from diabetes. According to the American Diabetes Association (ADA), rising incidence of type 2 diabetes in South Asia is likely to be over 150% between 2000 and 2035.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Arm/Leg Rest Market Industrial Progress 2018 to 2026 Wed, 19 Jun 2019 11:57:37 +0200 http://comunicati.net/comunicati/aziende/varie/570939.html http://comunicati.net/comunicati/aziende/varie/570939.html Coherent Market Insights Coherent Market Insights Arm/Leg rest is a feature that is found in wheelchairs, modern vehicles, aircrafts, and auditoriums where user can rest their arms or legs and able to balance their body. Placing the weight of arms on armrest reduces downward gravity acting on the spine and helps in improving posture, maintaining the integrity of the spine and intervertebral discs. Leg rests have an adjustable angle, which are removable and have calf pads that support lower part of the leg when elevated. Such features of arm/leg rest are helpful in spinal cord injury patients. Click To Read More On Arm/Leg Rest Market.

Arm/Leg Rest Market – Drivers

Research and development activities in arm/leg rest technology for the comfort of users is expected to propel growth of the arm/leg rest market. For instance, in 2018, Soarigami, developed a new, portable, and user friendly armrest device. Its stainless steel hardware adjusts to different arm widths with removable coverings and durability and facilitates its use in airplanes, trains, stadiums, and other places.

Arm/Leg Rest Market – Restraint

Difficulty in moving and height adjustment are reducing user compliance, which in turn is expected to restrain growth of the arm/leg rest market. For instance, according to report published by United Spinal Association, 2017, armrest contains movable parts, which tend to get damaged. Wheelchair armrests may also at times interfere with wheelchair propulsion, making wheels more difficult to move.

Arm/Leg Rest Market – Taxonomy

By Application

  • Arm Support

  • Leg Support

By End User

  • Hospitals

  • Specialty Clinics

  • Ambulatory Surgical Centers

  • Home Care Settings

  • Rehabilitation Centers

Arm/Leg Rest Market – Regional Analysis

On the basis of region, the arm/leg rest market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected hold a dominant position in the global arm/leg rest market over the forecast period. This is owing to increasing prevalence of spinal cord injuries, which further result in arm and legs disabilities. For instance, according to Spinal Cordcom statistics, 2017, around 17,500 new spinal cord injuries are registered in the U.S., annually.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2222

Furthermore, Europe is expected to witness significant growth in the arm/leg rest market, owing to new product launches. For instance, in March 2016, Yanfeng Automotive Interiors (YFAI), a Germany-based company, developed a new heated armrest for door panels of cars. Such armrest offers comfort, flexibility, and energy efficiency during winter.

Key players operating in the arm/leg rest market include, Inmoclinc s.a, Provita medical gmbh & co. kg., KOHLAS, Bristol Maid, Medi-Plinth, Cardinal Health, General Electric Company, and Better Mobility Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
CRISPR and CAS Gene Market is Anticipated to Show Growth by 2026 Mon, 10 Jun 2019 13:58:04 +0200 http://comunicati.net/comunicati/aziende/varie/567066.html http://comunicati.net/comunicati/aziende/varie/567066.html Coherent Market Insights Coherent Market Insights The CRISPR and CAS Gene Market size was valued at US$ 1,388.1 million in 2017, and is expected to witness a CAGR of 20.8% over the forecast period (2018 – 2026). CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential for the adaptive immunity in few bacteria and archaea, enabling the organisms to respond to and to eliminate invading genetic material. These gene editing tools are extensively used in agriculture and food security.

Many food and agricultural organizations are working on receiving license for using CRISPR and CAS gene technology for creating novel products in food and agriculture business. For instance, in September 2016, agrochemical and agricultural biotechnology corporation Monsanto secured a worldwide non-exclusive license agreement for agricultural applications of CRISPR technology from the Broad Institute. CRISPR and CAS genes are also used in treating a number of diseases such as cancer, blood disorders, AIDS, and genetic disorders such as cystic fibrosis, Huntington’s etc.

Market Dynamics

Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and Huntington’s disease worldwide is highly contributing to the market growth of CRISPR and CAS gene market, as many genetic disabilities can be corrected using this gene editing technology. According to National Health Service (NHS) U.K. 2018 report, the highest rate of Huntington’s disease in the United Kingdom is 12 per 100,000 people.

Government bodies are taking initiatives for developing treatment of Huntington’s disease. For instance, in 2016, US-based Company Addgene has developed the KamiCas9, a version of CRISPR-Cas9 that includes a ‘self-inactivating’ KamiCas9 system for the editing of CNS disease genes for treatment of Huntington’s disease.

Increasing Demand for Clinical Trials Coupled with Increasing Research & Development in CRISPR and CAS Gene therapy is expected to Drive Growth of the CRISPR and CAS Gene Market

Increasing research & development and demand for clinical trials for development of new technologies in CRISPR and CAS gene therapy for treatment of cancer is one of the major driving factor. For instance, The Parker Institute for Cancer Immunotherapy, a non-profit organization formed in April 2016, with a US$ 250 million grant from the Parker Foundation, agreed to sponsor the first in-human clinical trials of CRISPR-enabled technology targeting three types of cancer. The trial, led by the University of Pennsylvania, will use CRISPR-modified T-cells, a part of the human immune system, to treat myeloma, melanoma, and sarcoma. The trial was commenced in 2017.

CRISPR and CAS Gene Market - Competitive Landscape

Key players operating in the global CRISPR and CAS Gene market include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2598

CRISPR and CAS Gene Market - Regional Insights

On the basis of region, the global CRISPR and CAS Gene market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global CRISPR and CAS Gene market, owing to increasing number of the Food and Drug Administration (FDA) approval for clinical trial.

Asia Pacific is expected to foresee a rapid growth in the CRISPR and CAS Gene market over the forecast period. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to rise in the demand of CRISPR and CAS gene therapy especially in research activities. For instance, in May 2018 researchers at Kobe University in Japan successfully destroyed and deleted the regulatory genes of HIV-1 using the genome editing system CRISPR/Cas9, thereby successfully blocking the production of HIV-1 by infected cells.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Infant Incubator Market Projected to witness a Single Digit CAGR during 2018 - 2026 Fri, 07 Jun 2019 14:57:08 +0200 http://comunicati.net/comunicati/aziende/varie/566615.html http://comunicati.net/comunicati/aziende/varie/566615.html Coherent Market Insights Coherent Market Insights Infant incubator is a device used for pre-matured infants, which are born before 37 weeks of pregnancy period. These pre-termed infants undergo several complications as their body temperature is low, i.e., they cannot regulate the temperature of their body when born hence, have a high risk with respect to external environment, various infections, and breathing problems that can lead to death. Incubators protect premature infants by providing them the required environment. They are small box-like structures that contain small bed and an attached trolley. These boxes are generally made of glass except the top is covered by rigid plastic. Click To Read More On Infant Incubator Market.

Infant Incubator Market Drivers

Increasing number of premature infants is expected to boost the global infant incubator market growth over the forecast period. For instance, according to World Health Organization’s (WHO) report, 2018, around 15 million infants are born in a pre-mature state worldwide annually. The report also states that prematurity is one of the major contributors of infant mortality rate worldwide. The rate of babies born in a pre-mature state ranges from 5% - 8% in 184 countries.

Increasing number of studies are focused on advancements in infant incubator, which is expected to support the global infant incubator market growth over the forecast period. For instance, in March 2019, a group of researchers from Northwestern University and the Robert H. Lurie Children’s Hospital of Chicago developed wireless sensors and biosensors for monitoring vital signs with regards to contact of mother and child in replacement of wires that are used in incubator. According to the researchers, skin-to-skin contact between mother and child decreases the risk of pulmonary complications and liver infections. Implementation of such technologies in products available in the market is expected to support global infant incubator market growth over the forecast period.

Infant Incubator Market Restraint

High cost of infant incubator is expected to hinder the global infant incubator market growth over the forecast period. Manufacturers in the market are focused on offering technologically advanced (such as pressure diffusing mattresses and disposable skin probes) products in the market. This factor further adds to the final prices of these products. For instance, incubator may cost anywhere between US$ 600 to US$ 6,500 (GE Healthcare’s incubator costs around US$ 6,210). This factor may restrain the global infant incubator market growth in developing countries in regions such as Africa, Asia Pacific, and Latin America.

Infant Incubator Key Players

Some of the major players operating in global infant incubator market include, GE Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Bistos Co. Ltd., Drägerwerk AG & Co. KGaA, UTAH Medical Products Inc., and Inspiration Healthcare Group plc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2606

Infant Incubator Market Regional Analysis

North America is expected to hold dominant position in the global infant incubator market over the forecast period. This is owing to presence of major market players such as GE Healthcare, Natus Medical Corporation, and UTAH Medical Products Inc in the region. Moreover, potential customer base and initiatives of governments and several organizations (non-profit, and others) to increase the awareness about consistent rise in birth rate of premature infants is expected to support growth of the North America infant incubator market. For instance, March of Dime – a non-profit organization in the U.S. — celebrates November as a prematurity awareness month annually.

Moreover, Europe is expected to be the second largest market for infant incubator over the forecast period. Key players in the market are focused on participating and organizing conferences related to pre-mature birth. For instance, in March 2017, Inspiration Healthcare (U.K.-based manufacturer) sponsored a Neo-Resus conference held in the U.K. which was about neonatal resuscitation (reviving infants from unconsciousness or apparent death). These factors are expected to support the global infant incubator market growth over the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Automated Antimicrobial Susceptibility Testing Market Benefit and Volume 2018 with Status and Prospect to 2026 Fri, 07 Jun 2019 13:04:51 +0200 http://comunicati.net/comunicati/aziende/varie/566517.html http://comunicati.net/comunicati/aziende/varie/566517.html Coherent Market Insights Coherent Market Insights The Global Automated Antimicrobial Susceptibility Testing Market size was valued at US$ 1,295.5 million in 2018 and is expected to witness a CAGR of 8.9% over the forecast period (2018 – 2026). Automated antimicrobial susceptibility testing products are of two types, consumables and instruments. Consumables used in automated antimicrobial susceptibility testing includes culture & growth media, ready-to-use reagents, complete reagent kits, susceptibility disks, susceptibility plates, and susceptibility cards, among others. Key players offer reagent kits and disposables, which are designed for use with their automated AST instruments, which optimizes workflow and overall laboratory efficiency. Automated microbial identification and antimicrobial susceptibility testing (AST) instruments offer rapid, accurate, and efficient susceptibility testing, thereby enhancing workflow, reducing hands-on time, and enabling rapid reporting. Automated laboratory AST instruments are equipped with Laboratory Information System (LIS) compatible software to enable better compatibility.

Market Dynamics

Increasing prevalence of antibiotic resistance worldwide is expected to boost the automated antimicrobial susceptibility testing market growth. According to the World Health Organization’s Global Antimicrobial Surveillance System (GLASS) report of January 2018, antibiotic resistance is found among 500,000 people with suspected bacterial infections across 22 countries. The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella sp.

Emergence of multidrug resistance worldwide is expected to drive growth of the automated antimicrobial susceptibility testing market

Increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and others among the global population is expected to result in increasing adoption of antimicrobial susceptibility testing to reduce the resistance exposure during the forecast period. For instance, according to the World Health Organization (WHO), in 2014, there were around 480,000 new cases of multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Among these, only around 123,000 cases were detected and reported.

Moreover, increasing number of product launches is also expected to highly contribute to the automated antimicrobial susceptibility testing market growth. For instance, in March 2016, Becton, Dickinson and Company launched the new BD Phoenix M50 ID/AST system, which helps to deliver the same rapid, accurate, and cost-effective testing as the legacy BD Phoenix 100, within a small footprint.

Automated Antimicrobial Susceptibility Testing Market - Competitive Landscape

Key players operating in the global automated antimicrobial susceptibility testing market include bioMérieux S.A., HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, Resistell AG, Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Merck KGaA, and Bio-Rad Laboratories, Inc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2622

Automated Antimicrobial Susceptibility Testing Market - Regional Insights

On the basis of region, the global automated antimicrobial susceptibility testing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global automated antimicrobial susceptibility testing market during the forecast period, owing to development of new antimicrobial testing procedures and increasing awareness among people regarding antimicrobial resistance (AMR). For instance, in April 2018, the U.S. Food and Drug Administration approved Thermo Scientific Sensititre ID/AST System, the first to offer delafloxacin and meropenem/vaborbactam on IVD-labeled, microbroth dilution susceptibility plates. The antimicrobials are currently available in the U.S. on Sensititre custom plates and are expected be available soon in new standard formats.

Asia Pacific is expected to witness rapid growth in the automated antimicrobial susceptibility testing market, owing to high prevalence of microbial infections and increasing consumption of antibiotics, eventually developing resistance among the population. For instance, according to a 2014 WHO report, multidrug-resistant tuberculosis rates were high in India, especially among those who were previously treated and treatment for the disease is generally limited.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
India Immune-Oncology Drugs Market Expansion to be Persistent During 2018 – 2026 Fri, 07 Jun 2019 08:55:30 +0200 http://comunicati.net/comunicati/aziende/varie/566282.html http://comunicati.net/comunicati/aziende/varie/566282.html Coherent Market Insights Coherent Market Insights Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah. India Immune-Oncology Drugs Market size was valued at US$ 172.8 million in 2018 and is expected to witness a CAGR of 13.1% over the forecast period (2018 – 2026).

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

Increasing Incidences of Cancer Cases and Introduction of Novel Immuno-Oncology Therapies is expected to Drive Growth of the India Immune-Oncology Drugs Market

Rising incidences of cancer in India is expected to boost the immuno-oncology drugs market during the forecast period. For instance, according to Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The immune-oncology drugs market is expected to generate a high revenue, owing to increasing introduction of new novel therapies for treatment of cancer with improved therapeutic outcomes that have led to increasing success rates against cancer. Novel immune therapies can restore the ability of immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available.

India Immune-Oncology Drugs Market - Competitive Landscape

Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2631

Detailed Segmentation:

  • India Immuno-Oncology Drugs Market, By Drug Type:

    • Immune Checkpoint Inhibitors

      • Nivolumab (Opdivo)

      • Atezolimumab (Tecentriq)

      • Pembrolizumab (Keytruda)

      • Durvalumab (Imfinzi)

    • Monoclonal Antibodies

      • Rituximab (Rituxan)

      • Trastazumab (Herceptin)

      • Bevacizumab (Avastin)

      • Nimotuzumab (Biomab EGFR)

      • Pertuzumab (Perjeta)

      • Ado-Trastuzumab Emtansine (Kadcyla)

    • Cancer Vaccines

      • Gardasil

      • Cervarix

India Immune-Oncology Drugs Market - Restraints

Major restraining factors for India immune-oncology drugs market include inadequate delivery of affordable and equitable cancer care drugs in India, which hampers the India immune-oncology drugs market. For instance, according to the data published in Lancet Journal in 2014, public expenditure on cancer in India remains below US$ 10 per person (compared to over US$ 100 per person in high-income or developed countries) and overall public expenditure on healthcare is still only slightly above 1% of the gross domestic product.

According to the same source, out-of-pocket payments, which account for over three-quarter of cancer expenditures in India are one of the greatest threats to patients and families. Moreover, higher effectiveness of cancer drugs and comparatively less availability of better alternative results restricts key players to drive down cost of cancer drugs.

About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Medical Device Outsourcing Market To See Incredible Growth By 2026 Thu, 06 Jun 2019 14:19:24 +0200 http://comunicati.net/comunicati/aziende/varie/566049.html http://comunicati.net/comunicati/aziende/varie/566049.html Coherent Market Insights Coherent Market Insights Medical device outsourcing market is the phenomenon that emphasize on contracting with third party for product design, manufacturing, packaging, validation, prototyping and verification of medical devices in sterile and controlled environment for supply chain management. Outsourcing not only saves the resources and decreased the operating cost but also offers the opportunities for core activities. Medical device industry has the huge pain point in terms of vendor management and relationships. The medical device outsourcing are mainly controlled by the rising demand for quality of medical products and healthcare services. The manufacturers are looking for the option to outsource their medical device manufacturing processes to the third party medical contract manufacturers, thus the medical device outsourcing market is experienced to grow upward on a global level. Click to Read More On Medical Device Outsourcing Market.

Medical Device Outsourcing Market - Drivers

Increasing prevalence cardiovascular diseases drives the growth of medical device outsourcing market. According to the American Heart Association, 2016, cardiovascular diseases account for 17.3 million deaths every year globally, where an estimated 23.3 million people are expected to die from CVD by 2030, thus illustrating the rising need to adopt devices. Also, according to American Heart Association, in 2019, 48% i.e. nearly half of all adults in U.S. have some type of cardiovascular diseases.

Moreover, manufacturers are developing well established strategies by undergoing acquisition to become the leading supplier minimally invasive medical device delivery and access devices which serves medical devices original equipment manufacturers (OME). For instance, in 2016, TE Connectivity Ltd., announced that it has entered into the agreement to acquire the Creganna Medical Group.

The acquisition of Creganna Medical is a part of well-established strategy to expand the leadership position of TE connectivity in harsh environment. Medical device outsourcing provides the instant insights about health status thereby, providing significant opportunities in improving medical device outsourcing. For instance, the key players in developing countries of Asia Pacific and Latin America produce the considerable increase in the revenue due to the growth in the opportunities which is offered by these regions.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2641

Medical Device Outsourcing Market - Competitive Landscape

The market share of key players is increased by growing number of acquisitions in coming years. For instance, in 2016, Cirtec Medical acquired the Stellar Technologies Inc., a components manufacturer to improve the technology for customers in neuromodulation market. Similarly, in July 2017, GE Healthcare announced the acquisition on Novia Strategies, Inc., which help the healthcare firms to meet the market demand for growing access.

Some of the key players operating in the global medical device outsourcing market include Onex Corporation, Cardinal Health, Inc., Integer Holdings Corporation, TE Connectivity Ltd., Flex Ltd., Heraeus Holding GmbH, Plexus Corporation, Sanmina Corporation, West Pharmaceutical Services, Inc.

Medical Device Outsourcing Market - Regional Insights

On the basis of region, the medical device outsourcing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the medical device outsourcing market, owing to existence of advanced technological electronic sector, large number of medical device manufacturers. Increasing demand for medical devices like wearable devices, owing to increase prevalence of chronic diseases that fuels the regional market growth. According to the National Health Council, 2015, chronic diseases affect over 70 million individuals in the U.S., which accounts for over 75% of the healthcare expenditures equaling to around US$ 2 trillion.

Asia Pacific is expected to gain the fastest growth in demand for medical device outsourcing during forecast period, as it consists of tax breaks and incentives such as lower tariffs and duties to foreign companies in this nations offer an opportunity for market growth.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>
Surgical Drainage Devices Market Advancements to Watch Out For 2026 Thu, 06 Jun 2019 11:43:34 +0200 http://comunicati.net/comunicati/aziende/varie/565915.html http://comunicati.net/comunicati/aziende/varie/565915.html Coherent Market Insights Coherent Market Insights A surgical drainage device is an equipment that removes excess fluid or air or infected blood from the operation site or wound so that the risk of formation of hematoma is reduced and wound healing process is accelerated to ensure speedy recovery of the patient. Surgical drainage devices consist of soft pliable tubes, which are used to remove the pus, blood, and fluid from the wound, preventing it from accumulating in the body. There are various types of drain such as Jackson Pratt drain, Blake drain, Penrose drain, Chest tube, and Redivac drain. Click To Read More On Surgical Drainage Devices Market.

Global Surgical Drainage Devices Market - Drivers

Increasing geriatric population, rise in number of surgeries, and increase in incidences of target diseases, globally are major drivers of the market. Furthermore, increased tobacco and alcohol consumption, rise in number of cancer-related surgeries, and increasing demand for minimally invasive surgeries are factors driving the market globally. The manufacturers are launching innovative surgical drainage devices in the market to meet the unmet needs of patients which gives the significant opportunities for existing players and new entrants.

Moreover, the medical technological companies are focused on undertaking strategic acquisitions to strengthen the product portfolio, thereby enhancing opportunities in fast growing clinical areas in non U.S. markets. For instance, in April 2017, Becton, Dickinson and Company (BD), a global medical technology company and Bard, Inc., a medical technology leader in urology, oncology, and surgical specialty products entered into an agreement, under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for the total consideration of $24 billion. This acquisition will lead to improve process of care and treatment of disease for patients and healthcare providers.

Global Surgical Drainage Devices Market - Competitive Landscape

The key players develop new and innovative drainage devices for patients to treat eye-related disorders. For instance, in November 2018, Purdue University invented a new smart drainage device to help patients with glaucoma, a leading cause of blindness in the world, which tries to save their eyesight.

Some of the key players operating in the global surgical drainage devices market include B. Braun Melsungen AG, Teleflex Incorporated, Stryker, Johnson and Johnson, REDAX, Smith and Nephew plc, Integra LifeSciences, Medela AG, Acelity L.P. Inc., Cardinal Health, Ethicon, C.R. Bard, and Cook Medical.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2648

Global Surgical Drainage Devices Market - Regional Insights

North America holds dominant position in the global surgical drainage devices market, owing to increase in number of orthopedic surgeries such as hip replacement and knee replacement. In 2017, North America held dominant position in the market followed by Europe, due to key factors such as rise in incidence of chronic wounds, surgical site infections, rise in geriatric population, and higher adoption and awareness of advanced surgical and wound care products.

Asia Pacific is expected to gain significant traction in the global surgical drainage devices market over the forecast period. The market grows in this region, due to rise in population in India and China, rise in trauma and burn cases, and development in healthcare infrastructure. Moreover, rising adoption of technologically advanced medical equipment and trend of cost-effective health care services are factors driving growth of surgical drainage devices market in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

]]>